Start Date
July 31, 2000
Study Completion Date
October 31, 2005
gemcitabine hydrochloride
paclitaxel
HemOnCare, P.C., Brooklyn
Interlakes Oncology/Hematology PC, Rochester
Rittenhouse Hematology/Oncology, Philadelphia
Northern Virginia Oncology Group, P.C., Fairfax
N.W. Carolina Oncology & Hematology, P.A., Hickory
South Carolina Oncology Associates, Columbia
Mercy Hospital, Miami
Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton
Comprehensive Cancer Institute of Huntsville, Huntsville
Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, Memphis
Office Of C. Michael Jones, Germantown
University of Tennessee, Memphis, Memphis
North Mississippi Hematology and Oncology Associates, Ltd., Tupelo
Indiana Community Cancer Care, Inc., Indianapolis
Cancer Health Associates, Michigan City
Carle Cancer Center, Urbana
Memorial Medical Center, Springfield
St. John's Mercy Medical Center, St Louis
Little Rock Hematology-Oncology Associates, Little Rock
Oklahoma Oncology Inc., Tulsa
Arlington Cancer Center, Arlington
Southwest Regional Cancer Center, Austin
University of Colorado Cancer Center, Denver
Mountain States Tumor Institute, Boise
Intermountain Hematology/Oncology Associates, Inc., Salt Lake City
Office of Alex J.P. Makalinao, Los Angeles
Pacific Coast Hematology/Oncology Medical Group, Fountain Valley
Hematology/Oncology Group, Santa Rosa
Danbury Internal Medicine, Danbury
APN-IMPATH Research Corporation, Fort Lee
Overlook Hospital, Summit
Eli Lilly and Company
INDUSTRY